Home » Merrimack Ends the Phase II Hermione Trial of MM-302
Merrimack Ends the Phase II Hermione Trial of MM-302
Cambridge, Massachusetts-based Merrimack Pharmaceuticals halted its Phase II study of MM-302 for the treatment of HER2-positive metastatic breast cancer in patients that have previously been treated with trastuzumab, pertuzumab and ado-trastuzumab emtansine.
The decision was based on findings that both the treatment and control arms were found to have shorter than expected median progression-free survival. Merrimack plans to provide more details in January 2017.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May